Monrovia, CA (PressExposure) April 05, 2014 -- Paul Juniewicz, Head of Oncology Business Opportunities, Strategic Portfolio and Management Group at Sanofi, will give a keynote presentation on the "Impact of Recent ASCO 2014 Perspective on Clinically Meaningful Outcomes on Oncology Drug Development and Deals/Partnership" at the 3rd Oncology Partnering & Deal-Making Conference to be held on July 7-8, 2014 in Boston, MA.
In March 2014, ASCO issued a "perspective" on raising the bar for clinical trials by defining clinically meaningful outcomes (JCO March 17, 2014) in which it was recommended that for advanced pancreas, lung, breast and colon cancer, there should be a larger improvement in overall survival (OS) and progression-free survival (PFS) for new therapies. The impact of the recent ASCO perspective on drug development, Regulatory and HTA reviews and deals/partnerships, will also be discussed. Discussion will include clarification on "clinically meaningful outcomes" as it is related to indication and setting; rationale to raise the bar in terms of patient benefit and regulatory approval and price/reimbursement; how these changes will effect drug development and Go/No-Go decisions.
Paul Juniewicz is currently the North American Head of Oncology Business Opportunities (OBO) within the Strategic Portfolio and Management Group of the Oncology Division for Sanofi. Juniewicz is responsible for scouting and evaluating external oncology opportunities, possible research collaborations and making recommendations on these external opportunities/ research collaborations to various senior management committees within Sanofi in Oncology, R&D as well as Business Development. The OBO Team works closely with all groups within the Oncology Division and in close collaboration with Business Development and the Strategy, External Innovation & Science Policy Department. Prior to this current role, Paul was most recently the Vice-President within the External Innovation Department of Sanofi-Aventis, Research and Development, while being responsible for scouting and evaluating early research opportunities across all therapeutic areas.
GTCBio's 3rd Oncology Partnering & Deal Making Conference is a partnership and business development conference that will provide an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in oncology that will affect the industry. Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, partnership opportunities, alliance management, value maximization vs. capital efficiency, and IPOs. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum!
This conference is part of the larger Novel Cancer Therapeutics Summit, which consist of two co-located parallel conferences: 3rd Oncology Partnering & Deal-making Conference 5th Cancer Targets & Therapeutics Conference
For more information, please visit http://www.gtcbio.com